We are live on ! Find out more
ACET icon

Adicet Bio
ACET

40 hedge funds and large institutions have $177M invested in Adicet Bio in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 6

64% more capital invested

Capital invested by funds: $108M → $177M (+$68.7M)

0.01% less ownership

Funds ownership: 0.38% → 0.37% (-0.01%)

11% less funds holding

Funds holding: 45 → 40 (-5)

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Holders
40
Holders Change
-5
Holders Change %
-11.11%
% of All Funds
0.91%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
4
Increased
21
Reduced
6
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$12.2M
2
Millennium Management
Millennium Management
New York
+$2.71M
3
SCM
Segantii Capital Management
Hong Kong
+$1.76M
4
BlackRock
BlackRock
New York
+$1.75M
5
DAM
Deltec Asset Management
New York
+$1.57M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$18.1M
2
SI
SCP Investment
California
-$893K
3
JP Morgan Chase
JP Morgan Chase
New York
-$873K
4
AG
Artal Group
Luxembourg
-$583K
5
VEA
Virtus ETF Advisers
New York
-$363K

ACET Hedge Fund Activity: Q3 2018 in Review

40 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q3 2018, worth a combined $177M — up 64% from $108M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ACET and 4 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 21 added.

The largest buyer was Jennison Associates, adding an estimated $12.2M. The largest seller was Fidelity Investments, exiting entirely with an estimated $18.1M sold.

  • 40 institutional investors held Adicet Bio (ACET) as of Q3 2018, down from 45 in Q2 2018.
  • Funds reported $177M of Adicet Bio stock for Q3 2018, up 64% quarter-over-quarter.
  • 4 funds opened new Adicet Bio positions in Q3 2018 and 9 closed out, a net change of -5 holders.
  • The largest Adicet Bio buyer in Q3 2018 was Jennison Associates, an estimated $12.2M added.
  • The largest Adicet Bio seller in Q3 2018 was Fidelity Investments, an estimated $18.1M sold.

Based on aggregated 13F filings for Q3 2018.